ArticleInternational journal of clinical and experimental medicine2015
ABCB1 polymorphism and susceptibility to acute lymphoblastic leukemia: a meta analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia.Frontiers in pharmacology · 2022Review
- State of Art of Cancer Pharmacogenomics in Latin American Populations.International journal of molecular sciences · 2017Review
- The effects ofResearch in pharmaceutical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA large body of studies has investigated the potential role of ABCB1 polymorphism in ALL susceptibility. However, the results are conflicting. The aim of the present meta-analysis was to define the effect of ABCB1 polymorphism on ALL risk.
methodsWe identified 8 eligible studies involving 1,308 cases and 1,427 controls through searching PubMed and Enbase databases. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to access the strength of the association with both fixed effects and random effect models.
resultsWe found ABCB1 polymorphism was associated with an increased risk of ALL under the homozygote genotypes (TT vs. CC: OR, 1.29, 95% CI, 1.08-1.54), the recessive model (TT vs. CT + CC: OR, 1.47, 95% CI, 1.02-2.13) and the allele model (T vs. C: OR, 1.14, 95% CI, 1.04-1.25). Similar results were indicated in Asian populations (TT vs. CC: OR, 1.79, 95% CI, 1.32-2.43; TT vs. CT + CC: OR, 2.55, 95% CI, 1.47-4.43; T vs. C: OR, 1.38, 95% CI, 1.18-1.62), but not in Caucasian populations.
conclusionsThese findings indicate that ABCB1 polymorphism may play a critical role in the development of ALL in Asians.
Indexed as
Identifiers
26221303PMC4509248W1013553640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.